IntraOmmaya compartmental radioimmunotherapy using 131 I-omburtamab —pharmacokinetic modeling to optimize therapeutic index

ConclusionThe 2-compartmental pharmacokinetic model when applied to intraOmmaya131I-omburtamab yielded both intuitive and nonintuitive therapeutic predictions. The potential advantage of further dose fractionization warrants clinical validation.Clinical trial registrationClinicalTrials.gov, NCT00089245.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research